Recombinant Human SerpinC1 / AntithrombinIII / ATIII Protein (His tag) 20µg

Recombinant Human SerpinC1 / AntithrombinIII / ATIII Protein (His tag) 20µg

Size

20µg

Catalog no.

PKSH031837-20µg

Price

626 EUR

Buy

Fusion tag

C-His

Mol Mass

50.5 kDa

Conjugation

histidine

AP Mol Mass

55-60 kDa

Accession

NP_000479.1

Group

recombinants

Expressed Host

HEK293 Cells

Sequence

Met 1-Lys 464

Source

Recombinants or rec. proteins

Purity

>95 % as determined by SDS-PAGE

Formulation

Lyophilized from sterile PBS, pH 7.4

Synonym

AT3;AT3D;ATIII;MGC22579;SerpinC1;THPH7

Reconstitution

Please refer to it for detailed information.

Endotoxin

<1.0 EU per µg as determined by the LAL method

Activity

Measured by its ability to inhibit thrombin (Sigma, Catalog # T4648)cleavage of a fluorogenic peptide substrate Boc-VPR-AMC.The IC50 value is < 5 nM.

Stability and Storage

Samples are stable for up to twelve months from date of receipt at -70℃.Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Shipping

In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Properties

Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.

Background

SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors, and has been found to be a marker for disseminated intravascular coagulation (DIC) and to be of prognostic significance in septic patients. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. Thus it is one of the most important coagulation inhibitors and the fundamental enzyme for the therapeutical action of heparin. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. ATIII mediates the promotion of prostaglandin release, an inhibitor of leucocyte activation and downregulator of many proinflammatory cytokines. Antithrombin III exerts anti-inflammatory properties in addition to its anti-coagulative mechanisms. In animal models of sepsis, ATIII affected cytokine plasma concentrations with a decrease of pro-inflammatory cytokines. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization.